May 28, 2017 5:15 AM ET

Biotechnology

Company Overview of Affibody Medical AB (publ)

Company Overview

Affibody Medical AB (publ), a biotechnology company, focuses on developing biopharmaceuticals based on its Affibody molecules and Albumod proprietary technology platforms in Sweden. The company’s Affibody technology includes the Affibody molecules, which are antibody mimetics that surpasses monoclonal antibodies and antibody fragments; and Albumod technology enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. It is involved in developing three therapeutic programs to prevent Alzheimer, autoimmune, and psoriasis diseases; and a diagnostic imaging program for metastatic breast cancer. The company was formerly known as Affibo...

Gunnar Asplunds Alle 24

Solna,  171 69

Sweden

Founded in 1998

29 Employees

Phone:

46 8 59 88 38 00

Key Executives for Affibody Medical AB (publ)

Chief Executive Officer and President
Age: 41
Co-Founder, Deputy Chairman and Member of Scientific Advisory Board
Age: 62
Co-Founder, Chief Business Officer and Member of Technical Advisory Board
Co-Founder and Senior Vice President of Operations
Age: 47
Co-Founder and Member of Scientific Advisory Board
Age: 78
Compensation as of Fiscal Year 2016.

Affibody Medical AB (publ) Key Developments

Affibody Medical AB (publ) to Report Q1, 2017 Results on May 19, 2017

Affibody Medical AB (publ) announced that they will report Q1, 2017 results on May 19, 2017

Affibody Medical AB (Publ) Reports Earnings Results for the Fourth Quarter and Full Year of 2016

Affibody Medical AB (publ) reported earnings results for the fourth quarter and full year of 2016. For the quarter, the company reported revenue of SEK 28.5 million against SEK 40.9 million a year ago. Operating profit was SEK 0.00 million against SEK 14.8 million a year ago. EBITDA was SEK 0.2 million against SEK 14.9 million a year ago. Net results were SEK 0.00 million against SEK 14.8 million a year ago. Cash out flow was SEK 29.1 million against SEK 14.4 million a year ago. For the year, the company reported revenue of SEK 104.6 million against SEK 90.0 million a year ago. Operating loss was SEK 7.5 million against operating profit was SEK 4.7 million a year ago. LBITDA was SEK 6.8 million against EBITDA of SEK 5.2 million a year ago. Net loss was SEK 7.5 million against net profit of SEK 4.5 million a year ago. Cash flow was SEK 120.1 million against cash outflow of SEK 28.8 million a year ago.

Affibody Medical AB (Publ) Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2016

Affibody Medical AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2016. For the quarter, the company reported revenue of SEK 21.5 million against 14.1 million a year ago. Operating loss for the quarter amounted to SEK 5.2 million against SEK 8.2 million a year ago. LBITDA for the quarter amounted to SEK 5.0 million against SEK against SEK 8.1 million a year ago. Net loss was SEK 5.2 million against SEK 8.2 million a year ago. Cash flow for the quarter was SEK 24.0 million against SEK 14.9 million a year ago. For the nine months, the company reported revenue of SEK 76.1 million against 49.1 million a year ago. Operating loss for the period amounted to SEK 7.5 million against SEK 10.1 million a year ago. LBITDA for the quarter amounted to SEK 7.0 million against SEK against SEK 9.7 million a year ago. Net loss was SEK 7.5 million against SEK 10.2 million a year ago. Cash flow for the quarter was SEK 149.2 million against negative cash flow of SEK 14.4 million a year ago.

Similar Private Companies By Industry

Company Name Region
Abera Bioscience AB Europe
AddBIO AB Europe
Adenovir Pharma AB Europe
Affibody Medical AB (publ) Europe
Akinion Pharmaceuticals AB Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Affibody Medical AB (publ), please visit www.affibody.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.